We therefore studied the effects of engineered HER-2 overexpression on TGF-β signaling in the MCF-7 and ZR-75-1 luminal breast cancer cell lines as it is not yet possible to routinely culture normal or immortalized (i.e. non-malignant) luminal mammary epithelial cells. This evidence concerns the gene ERBB2 and breast cancer.